Essential cookies by default. The browser ID, load-time metrics and error replays only run if you choose "Accept all".
Head-to-head evidence comparison — which supplement is right for you?
Berberine vs Colchicine: Berberine has the stronger overall evidence (7.5 vs 3/10); they're alternatives for inflammation-related symptoms — the best pick depends on your goals. Take the 2-minute quiz for a pick tailored to your goals.
Berberine wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Helped
4 of 4 studies with measurable effects showed benefit.
Top outcomes
Verdict
Mixed
1 of 3 studies with measurable effects showed benefit.
Top outcomes
A source-matched dose range is not available for this product and use.
With meals, Split into 2-3 doses
Berberine HCl capsules
A source-matched dose range is not available for this product and use.
If this treatment was prescribed for you, follow your prescriber’s directions. Do not change prescribed treatment because this page has no matched dose range.
Any time of day
and 3 more not shown
4-12 weeks
8-12 weeks
First 2 weeks
If on diabetes medications
Months to years
Weeks
Trial endpoints
Throughout use
Clinical Efficacy of Curcumin, Resveratrol, Silymarin, and Berberine on Cardio-Metabolic Risk Factors Among Patients With Type 2 Diabetes Mellitus: A Systemic Review and Bayesian Network Meta-Analysis
Phytotherapy research : PTR (2025) · Meta-Analysis · n=1337
For HbA1c, silymarin was more effective than resveratrol (MD -2.08, 95%Cl -3.50 to -0.72) (P < 0.05).
Effects of berberine and barberry on selected inflammatory biomarkers in adults: A systematic review and dose-response meta-analysis of randomized clinical trials
Phytotherapy research : PTR (2023) · Meta-Analysis · n=1600
In addition, the non-linear analysis showed a significant lowering effect of berberine/barberry on IL-6 and TNF-α levels in doses <1000 mg/day and less than 5 weeks of intervention.
Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial
JAMA network open (2025) · RCT · n=113
The study included 113 patients with T2D (mean [SD] age, 54.3 [10.6] years; 72 male [63.7%]) who were randomized.
Low-dose colchicine for secondary prevention of cardiovascular disease.
Journal of the American College of Cardiology (2013) · RCT · n=532
LoDoCo randomized trial of low-dose colchicine in stable coronary disease
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.
The New England journal of medicine (2019) · RCT
COLCOT randomized, placebo-controlled trial of colchicine 0.5 mg/day after MI
Colchicine for Secondary Prevention of Coronary Artery Disease: A Meta-Analysis of Randomised Controlled Trials.
Heart, lung & circulation (2022) · Meta-Analysis
Meta-analysis of colchicine trials for secondary cardiovascular prevention
Each group's adjusted mean. Study A of PMID 18442638: 36 adults with newly diagnosed type 2 diabetes after 2 months of diet alone, randomised to berberine or metformin, 500 mg three times daily for 13 weeks. Completers only (berberine n=15, metformin n=16, 3 and 2 withdrew for treatment failure). Metformin is an active comparator, there is no placebo arm. Arm means are before and after treatment, not between-arm differences. The extractor had the two arms swapped: the abstract gives the berberine group as FBG 10.6 to 6.9 and HbA1c 9.5 to 7.5, which is the second column pair of Table 2 (headed Berberine, n=15). Source: PMID 18442638.
Each group's adjusted mean. Study A of PMID 18442638: 36 adults with newly diagnosed type 2 diabetes after 2 months of diet alone, randomised to berberine or metformin, 500 mg three times daily for 13 weeks. Completers only (berberine n=15, metformin n=16, 3 and 2 withdrew for treatment failure). Metformin is an active comparator, there is no placebo arm. Arm means are before and after treatment, not between-arm differences. The extractor had the two arms swapped: the abstract gives the berberine group as FBG 10.6 to 6.9 and HbA1c 9.5 to 7.5, which is the second column pair of Table 2 (headed Berberine, n=15). Source: PMID 18442638.
The 1,000 mg point is a placebo-controlled trial of berberine 1.0 g daily for 3 months in 116 people with type 2 diabetes, where HbA1c fell from 7.5% to 6.6% and fasting glucose fell more than on placebo (PMID 18397984). The 1,500 mg point is two trials of 500 mg three times daily: one in 36 people with new type 2 diabetes where glucose fell with no significant difference from metformin in this small pilot, with transient stomach side effects in 34.5% (PMID 18442638), and a placebo-controlled pilot in 34 people with prediabetes where HbA1c fell from 6.40% to 5.43% (PMID 37679692). No trial compared doses. The separate study observations do not establish a flat dose-response, an optimal dose or the response between them. Lower doses were not tested for glucose in any cited trial.
Berberine has a higher evidence score (7.5/10 vs 3/10) and wins in 2 of 3 categories.
For inflammation-related symptoms, Colchicine has a higher relevance score (80 vs 70).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The honest tier list — proven staples vs situational vs mostly marketing. The hub the other guides feed into.
Which supplements clash with blood thinners, thyroid meds, antibiotics & more — and what to do.
What genuinely lowers LDL/triglycerides — and why "red yeast rice" is a statin in disguise.
Berberine, inositol, magnesium vs the cinnamon/chromium hype — and the med-interaction warning.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.